Michael Shetzline - 10 Mar 2026 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
SVP, CMO, Head-Res&Drug
Signature
/s/ Amir Vitale, Attorney-in-Fact
Issuer symbol
IRWD
Transactions as of
10 Mar 2026
Net transactions value
$0
Form type
4
Filing time
12 Mar 2026, 16:05:07 UTC
Previous filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shetzline Michael SVP, CMO, Head-Res&Drug C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON /s/ Amir Vitale, Attorney-in-Fact 12 Mar 2026 0001808509

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Award +136,612 +26% $0.000000* 658,037 10 Mar 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.